Economic Consequences of the Overuse of Short-Acting ß-Adrenergic Agonists in the Treatment of Asthma in Spain

Valero, A; Molina, J; Nuevo, J; Simon, S; Capel, M; Sicras-Mainar, A; Sicras-Navarro, A; Plaza, V.
J. investig. allergol. clin. immunol ; 33(2): 109-118, 2023. ilus, tab, graf
Artículo en Inglés | IBECS (España) | ID: ibc-219413

Documentos relacionados

  1. Economic Consequences of the Overuse of Short-Acting ß-Adrenergic Agonists in the Treatment of Asthma in Spain.
  2. Regional variation in prevalence of difficult-to-treat asthma and oral corticosteroid use for patients in Australia: heat map analysis.
  3. Short-acting ß<sub>2</sub>-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study.
  4. Extent, trends, and determinants of controller/reliever balance in mild asthma: a 14-year population-based study.
  5. Short-acting ß<sub>2</sub>-agonist prescription patterns in patients with asthma treated by specialists in Thailand: results from SABINA III.
  6. The use of short-acting beta-2 adrenergic receptor agonists for asthma increased among Finnish and Swedish children from 2006 to 2017.
  7. A longitudinal study of cannabis use increasing the use of asthma medication in young Norwegian adults.
  8. Pharmacological treatment of asthma in Sweden from 2005 to 2015.
  9. Impact of mepolizumab in patients with high-burden severe asthma within a managed care population.
  10. SYmbicort given as needed in mild asthma (SYGMA study): a retrospective subanalysis of the Russian population.